Hims & Hers Health (NYSE:HIMS) Stock Price Down 4.5% - Should You Sell?

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) dropped 4.5% on Monday . The company traded as low as $61.08 and last traded at $61.72. Approximately 16,376,933 shares traded hands during trading, a decline of 16% from the average daily volume of 19,391,193 shares. The stock had previously closed at $64.65.

Wall Street Analysts Forecast Growth

HIMS has been the topic of several research analyst reports. Bank of America raised their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Citigroup reissued a "sell" rating and set a $30.00 target price (up from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. UBS Group reaffirmed a "mixed" rating on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $37.67.

Hims & Hers Health Stock Performance

The business has a fifty day simple moving average of $35.44 and a 200-day simple moving average of $33.90. The firm has a market cap of $13.96 billion, a price-to-earnings ratio of 141.71 and a beta of 1.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. During the same period last year, the company earned $0.05 EPS. Hims & Hers Health's revenue for the quarter was up 110.7% compared to the same quarter last year. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the completion of the transaction, the chief executive officer now owns 97,687 shares of the company's stock, valued at $5,692,221.49. The trade was a 56.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Melissa Baird sold 33,333 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $25.78, for a total transaction of $859,324.74. Following the completion of the transaction, the chief operating officer now directly owns 805,083 shares in the company, valued at $20,755,039.74. The trade was a 3.98% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 563,973 shares of company stock worth $21,951,757. Insiders own 13.71% of the company's stock.

Institutional Trading of Hims & Hers Health

Several large investors have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC boosted its holdings in Hims & Hers Health by 15.7% in the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company's stock worth $49,000 after acquiring an additional 227 shares in the last quarter. Allworth Financial LP boosted its holdings in Hims & Hers Health by 20.0% in the first quarter. Allworth Financial LP now owns 2,006 shares of the company's stock worth $56,000 after purchasing an additional 334 shares during the last quarter. Signaturefd LLC grew its holdings in shares of Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after acquiring an additional 388 shares during the period. SlateStone Wealth LLC increased its position in shares of Hims & Hers Health by 4.0% during the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock valued at $257,000 after purchasing an additional 413 shares during the last quarter. Finally, Larson Financial Group LLC raised its position in Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock worth $42,000 after acquiring an additional 458 shares during the period. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.